The diagnostic sensitivity of circulating cardio-enriched microRNAs is increased after normalization of high-density lipoprotein levels

Ram, Thrishila Parshu; Fomison-Nurse, I.; Gandhi, Sophie; Coffey, Sean; Saxena, Pankaj; Galvin, Ivor F.; Bunton, Richard; Williams, Michael J.A.; Lamberts, Regis R.; Katare, Rajesh

doi:10.1016/j.ijcard.2017.01.119

Cited by 6 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biological behavior of HUVSMcs and HUVEcs allows them to serve an important role in restenosis and long-term occlusion of vein bridges following coronary angioplasty (41)(42)(43)(44). Increasing evidence has indicated that the abnormal expression of miRNAs serves an important role in transplanted vascular diseases and they have received much interest in the research of various diseases (21,(45)(46)(47). Proliferation, migration and phenotypic transformation of SMcs or endothelial cells are associated with various miRNAs (48) including miR-145 (49,50), miR-222 (51), miR-195 (52) and miR-21 (53).…”

Section: Discussionmentioning

confidence: 99%

Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7

Ren

Liang

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

coronary artery bypass graft (cABG) is one of the primary methods of treating coronary heart disease (cHd); however, vein graft restenosis is a major limiting factor of the effectiveness of cABG. Emerging evidence has indicated that miR-423 is associated with vascular diseases. Additionally, upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 (AdAMTS-7) contributes to neointima formation by promoting the proliferation and migration of vascular smooth muscle cells and inhibiting the proliferation and migration of endothelial cells. The aim of the present study was to examine the effects of miR-423 target, AdAMTS-7, on regulating vein graft disease and identify novel biomarkers for use in therapy of vein graft failure (VGF). Aberrant expression of miR-423 in plasma of patients with CHD prior to and following CABG confirms that miR-423 may be a suitable target for preventing VGF. Furthermore, a dual-luciferase reporter gene assay indicated that miR-423 directly interacted with AdAMTS-7 and suppressed its expression. Ectopic expression of miR-423 suppressed AdAMTS-7, resulting in decreased proliferation and migration rates of human umbilical vein smooth muscle cells by targeting AdAMTS-7, but resulted in increased proliferation and migration of human umbilical vein endothelial cells in vitro. Overexpression of miR-423 also enhanced re-endothelialization and decreased neointimal formation in a rat vein graft model. In conclusion, the results of the present study demonstrated that the miR-423/AdAMTS-7 axis may possess potential clinical value for the prevention and treatment of restenosis in patients with cHd following cABG.

show abstract

Section: Discussionmentioning

confidence: 99%

Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7

Ren

Liang

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Several angiogenesis and inflammation-associated miRNAs, including miR-92a, miR-126, miR-150, miR-378, and miR-486 were also found in circulating HDL of patients with CAD ( 288 , 291 ). A recent study revealed that normalization of miRNAs with HDL level shows significant decrease in cardio-enriched miRNAs (particularly miR-1, 133, and 499) in diabetic patients undergoing coronary artery bypass graft (CABG) surgery for ischemic heart disease ( 292 ). The study proposed the need to normalize miRNA levels with HDL to increase its sensitivity as a diagnostic biomarker.…”

Section: Ncrna As Predictors and Prognostic Tools In Cvdmentioning

confidence: 99%

Deciphering Non-coding RNAs in Cardiovascular Health and Disease

Das

Samidurai

Salloum

2018

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

After being long considered as “junk” in the human genome, non-coding RNAs (ncRNAs) currently represent one of the newest frontiers in cardiovascular disease (CVD) since they have emerged in recent years as potential therapeutic targets. Different types of ncRNAs exist, including small ncRNAs that have fewer than 200 nucleotides, which are mostly known as microRNAs (miRNAs), and long ncRNAs that have more than 200 nucleotides. Recent discoveries on the role of ncRNAs in epigenetic and transcriptional regulation, atherosclerosis, myocardial ischemia/reperfusion (I/R) injury and infarction (MI), adverse cardiac remodeling and hypertrophy, insulin resistance, and diabetic cardiomyopathy prompted vast interest in exploring candidate ncRNAs for utilization as potential therapeutic targets and/or diagnostic/prognostic biomarkers in CVDs. This review will discuss our current knowledge concerning the roles of different types of ncRNAs in cardiovascular health and disease and provide some insight on the cardioprotective signaling pathways elicited by the non-coding genome. We will highlight important basic and clinical breakthroughs that support employing ncRNAs for treatment or early diagnosis of a variety of CVDs, and also depict the most relevant limitations that challenge this novel therapeutic approach.

show abstract

“…Researchers in this regard compare the expression level between patients and healthy controls to investigate their specific role as molecular biomarkers for IHD [ 19 ]. Circulating miRNAs are protected from the endogenous ribonuclease (RNases) activity by transport particles such as exosomes, microvesicles, or through binding to a protein complex or high-density lipoproteins (HDL) [ 20 , 21 ] ( Figure 1 ). Mainly, extracellular vesicle-carried miRNAs have been reported as significantly expressed in IHD-DM patients and have excellent diagnostic efficacy [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Kong

Lai

Lim

et al. 2022

IJMS

View full text Add to dashboard Cite

Ischemic heart disease (IHD) constitutes the leading global cause of mortality and morbidity. Although significant progress has been achieved in the diagnosis, treatment, and prognosis of IHD, more robust diagnostic biomarkers and therapeutic interventions are still needed to circumvent the increasing incidence of IHD. MicroRNAs (miRNAs) are critical regulators of cardiovascular function and are involved in various facets of cardiovascular biology. While the knowledge of the role of miRNAs in IHD as diagnostic biomarkers has improved, research emphasis on how miRNAs can be effectively used for diagnosis and prognosis of IHD is crucial. This review provides an overview of the biology, therapeutic and diagnostic potential, as well as the caveats of using miRNAs in IHD based on existing research.

show abstract

The diagnostic sensitivity of circulating cardio-enriched microRNAs is increased after normalization of high-density lipoprotein levels

Cited by 6 publications

References 16 publications

Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7

Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7

Deciphering Non-coding RNAs in Cardiovascular Health and Disease

miRNA in Ischemic Heart Disease and Its Potential as Biomarkers: A Comprehensive Review

Contact Info

Product

Resources

About